AJMC - Managed Care News, Research, and Expert Insights

Retrospective Real-World Analysis: Costs of First-Line Treatment of CLL/SLL With BTK Inhibitors

Retrospective

Real-World Analysis:

Costs of First-Line

Treatment of

CLL/SLL With

BTK Inhibitors

The following content is intended for US Healthcare Decision Makers only and is approved for use with a limited audience of payers, formulary committees, or other similar entities. This real-world study was not designed to draw any conclusions regarding safety or efficacy.

Please click here for the full US Prescribing Information.

The following content is intended for US Healthcare Decision Makers only and is approved for use with a limited audience of payers, formulary committees, or other similar entities. This real-world study was not designed to draw any conclusions regarding safety or efficacy.

Please click here for the full US Prescribing Information.

Clinical Perspectives Presented by:

Alyssa Davis, PharmD

Associate Director, Medical Access Strategy

Medical Affairs + Health Impact (Hematology)

AbbVie

Clinical Perspectives Presented by:

Alyssa Davis, PharmD

Associate Director, Medical Access Strategy

Medical Affairs + Health Impact (Hematology)

AbbVie

This study and video were supported by AbbVie US Medical Affairs

This study and video were supported by

AbbVie US Medical Affairs

BTKI-US-00051-MC 10/26